COMPARISON OF THE EFFICACY AND SAFETY OF CYCLOPHOSPHAMIDE (SP) AND RITUXIMAB (RTM) IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) WITH INTERSTITIAL LUNG DISEASE (ILD)

被引：0
|
作者：
Koneva, O. [1 ]
Ananieva, L. [1 ]
Garzanova, L. [1 ]
Desinova, O. [2 ]
Ovsyannikova, O. [1 ]
Starovoytova, M. [1 ]
机构：
[1] VA Nasonova Res Inst Rheumatol, Lab Microcirculat & Inflammat, Moscow, Russia
[2] Koneva Olga, Lab Microcirculat & Inflamat, Moscow, Russia
来源：
CHEST | 2020年 / 157卷 / 06期
关键词：
systemic sclerosis; rituximab; interstitial lung disease;
D O I：
10.1016/j.chest.2020.05.417
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：373A / 373A
页数：1
相关论文
共 50 条
  • [1] COMPARISON OF THE RITUXIMAB (RTM) IN MONOTHERAPY REGIMEN AND CYCLOPHOSPHOMIDE (CYP) EFFICACY AND SAFETY IN SYSTEMIC SCLEROSIS (SSC) WITH INTERSTITIAL LUNG DISEASE (ILD)
    Koneva, O.
    Ananieva, L.
    Garzanova, L.
    Desinova, O.
    Ovsyannikova, O.
    Starovoytova, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1584 - 1585
  • [2] COMPARISON OF THE RITUXIMAB(RTM) IN MONOTHERAPY REGIMEN AND MYCOPHENOLATE MOFETIL (MMF) EFFICACY AND SAFETY IN SYSTEMIC SCLEROSIS (SSC) WITH INTERSTITIAL LUNG DISEASE (ILD)
    Koneva, O.
    Ananieva, L.
    Garzanova, L.
    Desinova, O.
    Ovsyannikova, O.
    Starovoytova, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 704 - 704
  • [3] COMPARISON OF THE RITUXIMAB (RTM) EFFICACY IN MONOTHERAPY REGIMEN AND IN COMBINATION WITH IMMUNOSUPPRESSANTS IN SYSTEMIC SCLEROSIS (SSC) WITH INTERSTITIAL LUNG DISEASE (ILD)
    Koneva, O.
    Ananieva, L.
    Garzanova, L.
    Desinova, O.
    Ovsyannikova, O.
    Starovoytova, M.
    CHEST, 2020, 157 (06) : 374A - 374A
  • [4] RITUXIMAB AND CYCLOPHOSPHAMIDE COMPARISON FOR EFFICACY AND SAFETY IN THE PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE
    Koneva, Olga
    Ananyeva, Lidia P.
    Garzanova, Liudmila
    Desinova, Oxana
    Ovsyannikova, Olga
    Starovoytova, Mayya
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 169 - 169
  • [5] COMPARISON OF LONG-TERM CYCLOPHOSPHAMIDE (CY) AND MYCOPHENOLATE MOFETIL (MMF) EFFICACY AND SAFETY IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND INTERSTITIAL LUNG DISEASE (ILD)
    Koneva, O.
    Ovsyannikova, O.
    Desiniva, O.
    Garzanova, L.
    Ananieva, L.
    Starovoytova, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1108 - 1109
  • [6] RESULTS OF LONG-TERM (36 MONTHS) USE OF RITUXIMAB (RTM) AND IMMUNOSUPPRESSANTS (IS) IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) WITH INTERSTITIAL LUNG DISEASE (ILD)
    Koneva, Olga
    Garzanova, Liudmila
    Ovsynnikova, Olga
    Desinova, Oxana
    Ananyeva, Lidia
    Shayakhmetova, Rushana
    Starovoytova, Mayya
    Glukhova, Svetlana I.
    CHEST, 2022, 162 (04) : 2181A - 2182A
  • [7] Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
    Cottin, Vincent
    Brown, Kevin K.
    RESPIRATORY RESEARCH, 2019, 20 (1)
  • [8] Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
    Vincent Cottin
    Kevin K. Brown
    Respiratory Research, 20
  • [9] MYCOPHENOLATE MOPHETIL IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE (SSC-ILD) IN PATIENTS UNRESPONSIVE TO CYCLOPHOSPHAMIDE (CYC)
    Cuomo, G.
    Abignano, G.
    Iudici, M.
    Petrillo, A.
    Valentini, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S167 - S167
  • [10] Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
    Cole, Alice
    Denton, Christopher P.
    CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY, 2022, 8 (04) : 152 - 170
12345